SAN DIEGO, Sept. 30, 2021 /PRNewswire/ -- Regulus
Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company
focused on the discovery and development of innovative medicines
targeting microRNAs (the "Company" or "Regulus"), today announced
that David Baltimore, Ph.D., a
director of Regulus, is the recipient of the 2021 Lasker-Koshland
Special Achievement Award in the category of Medical Science.
Dr. Baltimore's recognition is based on the breadth and
substance of his discoveries in virology, immunology, and cancer as
well as his leadership within the academic and scientific
communities and his extensive work as a public advocate for
science.
The Lasker Awards program honors discoveries and clinical
advances that improve human health and highlights the importance of
public support for science. The awards program is widely considered
one of the most prestigious awards programs in medical science and
numerous recipients, including Dr. Baltimore, also hold Nobel
Prizes.
"On behalf of the Regulus team, we congratulate David for this
recognition of his extensive and impressive body of work," said
Jay Hagan, President and Chief
Executive Officer of Regulus. "As a 1975 Nobel Prize winner in
Physiology or Medicine, David has made multiple foundational
scientific discoveries over the course of his career, including the
discovery of reverse transcriptase, as well as his additional
research, which has contributed broadly to our understanding of
cancer, AIDS, and the underlying biology of the immune response. He
has been a powerful advocate for science over the years, advancing
work that helped America respond to the AIDS crisis, and has played
a significant role in the development of the biotechnology industry
in America. We are proud that he is a part of Regulus and
continually benefit from his guidance as we advance our pipeline of
microRNA therapeutics."
More information about the foundation and the Special
Achievement Award can be found here.
About David Baltimore,
Ph.D.
Dr. David Baltimore is a Director
of Regulus and President Emeritus and Distinguished Professor of
Biology at Caltech. Awarded the Nobel Prize in 1975, Dr. Baltimore
has profoundly influenced national science policy on such issues as
recombinant DNA research and the AIDS epidemic. Dr. Baltimore
graduated from Swarthmore College with
a degree in chemistry. He took graduate courses at Massachusetts Institute of Technology and received
his Ph.D. from Rockefeller University.
He was a postdoctoral fellow at MIT and
Albert Einstein College of Medicine.
He was a Research Associate at The Salk Institute in 1965 and
joined the faculty at MIT in 1968. He
has served as Director of the Whitehead Institute for Biomedical
Research, President of Rockefeller
University, and President of Caltech. He was awarded the
1999 National Medal of Science and 2000 Warren Alpert Foundation
Prize. He is a member of the National Academy of Sciences, fellow
of the American Academy of Arts and Sciences, and a foreign member
of the Royal Society of London and
the French Academy of Sciences. He has also been President and
Chair of the American Association of the Advancement of
Science.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical
company focused on the discovery and development of innovative
medicines targeting microRNAs. Regulus has leveraged its
oligonucleotide drug discovery and development expertise to develop
a pipeline complemented by a rich intellectual property estate in
the microRNA field. Regulus maintains its corporate headquarters in
San Diego, CA.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements regarding the Company's expected cash
runway and statements associated with the Company's RGLS4326
program, including the potential sufficiency of the data required
to recommence clinical studies for extended duration dosing, the
timing of the Company's interactions with FDA regarding the
clinical hold, the expected timing for reporting topline data, and
the timing and future occurrence of other preclinical and clinical
activities. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Words such
as "believes," "anticipates," "plans," "expects," "intends,"
"will," "goal," "potential" and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon Regulus' current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could
differ materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties, which
include, without limitation, risks associated with the process of
discovering, developing and commercializing drugs that are safe and
effective for use as human therapeutics and in the endeavor of
building a business around such drugs, the risk that feedback from
the FDA may be negative or may not be provided when we expect,
risks associated with our need for additional capital. In addition,
while Regulus expects the COVID-19 pandemic to adversely affect its
business operations and financial results, the extent of the impact
on Regulus' ability to achieve its preclinical and clinical
development objectives and the value of and market for its common
stock, will depend on future developments that are highly uncertain
and cannot be predicted with confidence at this time, such as the
ultimate duration of the pandemic, travel restrictions,
quarantines, social distancing and business closure requirements in
the U.S. and in other countries, and the effectiveness of actions
taken globally to contain and treat the disease. These and
other risks are described in additional detail in Regulus' filings
with the Securities and Exchange Commission, including under the
"Risk Factors" heading of Regulus most recently quarterly report on
Form 10-Q. All forward-looking statements contained in this
press release speak only as of the date on which they were made.
Regulus undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regulus-therapeutics-director-david-baltimore-receives-2021-lasker-koshland-special-achievement-award-in-medical-science-301389342.html
SOURCE Regulus Therapeutics Inc.